Business Wire

FourKites Appoints New President Rocky Subramanian to Accelerate Global Expansion

6.4.2023 11:08:00 EEST | Business Wire | Press release

Share

Leading supply chain visibility company FourKites today announces the appointment of Rocky Subramanian as President, effective immediately. Widely respected as a trusted advisor to leaders executing complex digital transformation at organisations of all sizes, Subramanian will work alongside CEO Mathew Elenjickal to drive the company's strategy, growth and customer success globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230406005293/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

FourKites announces the appointment of Rocky Subramanian as President (Photo: Business Wire)

“As our new President, Rocky will be key to taking FourKites to the next level,” said Elenjickal. “He has a proven track record in delivering big wins for customers, building world-class teams, championing workplace diversity and culture, scaling processes and growing thriving partner ecosystems. Just as important, he passionately shares my belief that better supply chains make the world a better place. I’m honoured to welcome him to our executive team as we accelerate FourKites’ growth trajectory.”

Subramanian was most recently Executive Vice President and CRO at Ceridian (NYSE:CDAY), where he helped the company grow to over $1.2B in revenue, added some of the biggest global brands as customers, and transformed the revenue organisation. He previously served as Senior Vice President and Managing Director of one of SAP’s (NYSE:SAP) largest market units — with responsibilities spanning sales, go-to-market strategy, operations and services for the entire enterprise software portfolio — which he grew to over $1.8B. Prior to SAP, Subramanian served in various roles at Oracle/PeopleSoft (NYSE:ORCL), Renaissance and NCS Pearson. He also advises as a volunteer mentor, and supports organisations with missions focused on education accessibility and eradicating hunger.

“From the beginning, I have been inspired by FourKites’ vision. It goes far beyond visibility; FourKites is helping companies lower costs, improve customer satisfaction, enhance workplace productivity and achieve their sustainability goals. It’s helping get food, medication and critical supplies to people who need them — faster and more reliably than ever before,” said Subramanian. “Paired with the company’s world-class products, pace of innovation, rapid deployment, thriving partner ecosystem and the scale at which we can help our customers, the potential for FourKites’ global impact is limitless. I’m excited and proud to join Matt and the entire FourKites team on this mission.”

Subramanian’s appointment comes on the heels of significant momentum for FourKites. In 2022, the company realised 70% growth in new customers, with more than 1,200 of the world’s most recognised brands — including 50% of the Fortune 500 — now using FourKites to track more than 3 million shipments around the world every day. In addition to strategic investments in 2021 from industry heavyweights Qualcomm Ventures, LLC, Volvo Group Venture Capital AB and Zebra Technologies, over the past year, FourKites inked strategic partnerships with a number of industry titans to continue executing on its bold vision to provide visibility everywhere. These companies include Mitsui & Co., Ltd., Quiet Platforms, Sony, Microsoft and Narvar. The real-time supply chain visibility pioneer was also recognised for its industry leadership and ongoing innovation by Gartner, SupplyChainBrain, Blue Yonder, Builtin Chicago, Manhattan Associates and Food Shippers of America.

FourKites continues to attract top talent to its senior leadership team as it scales its global operations and reinforces its focus on customer success. In addition to Subramanian, the company recently announced the appointment of Rebecca Nerad as Vice President of Global Customer Success, and Natalie Wolf, Vice President of Customer Operations and Strategy. Nerad has over 20 years in the supply chain industry, having held senior customer success roles at e2open, i2 Technologies, JDA Software and Bristlecone, while Wolf has held senior customer experience roles at Anaplan and Celonis.

About FourKites

Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 3 million shipments daily across road, rail, ocean, air, parcel and last mile, and reaching over 200 countries and territories, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,200 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Scott Johnston
FourKites European PR Director
+31 62 147 8442
scott.johnston@fourkites.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye